The Johns Hopkins University

Conopco, Inc.

Unilever Plc

Unilever, N.v.

Qingguo Xu

Justin Scot Hanes

Hai-Quan Mao

Peter John McDonnell

Shuming Zhang

Fabiana Kimie Kashiwabuchi

Barbara S Slusher

Jin Yang

Jeffrey L Cleland

Ming Yang

Jie Fu

Penelope Eileen Knight

Shiping Zhu

Deborah Lynne Aldred

Jan Alders Wieringa

Arjen Bot

Walter J Stark

Anne Le

Kunal S Parikh

Bing Wang

Jinfeng Peng

Qing Pan

Nicholas J Boylan

Lixia Luo

Joshua Kays

Nicholas Boylan

Yun Yu

Andrea Williams

Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into 'soluble' colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.

Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy

The present invention relates to a method for the production of aerated water-in-oil emulsions containing sucrose fatty acid esters. The invention further relates to aerated water-in-oil emulsions containing sucrose fatty acid esters, and to use of the composition for shallow flying and baking of food products. The method comprises a step wherein an oil is mixed with sucrose fatty acid ester, followed by aeration of this mixture. The obtained foamed oil is mixed with a water-in-oil emulsion.

Method for production of aerated water-in-oil emulsions and aerated emulsions

Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer. In a preferred embodiment the suture materials are made from a poly(hydroxyl acid) such as poly(1-lactic acid) and a polyalkylene oxide such as poly(ethylene glycol) or a polyalkylene oxide block copolymer. The sutures entrap (e.g., encapsulate) one or more therapeutic, prophylactic or diagnostic agents and provide prolonged release over a period of at least a week, preferably a month.

Methods of making drug loaded microfiber sutures for ophthalmic application

Particles encapsulating a glucocorticoid such as dexamethasone sodium phosphate (DSP) into a matrix such as biodegradable poly(lactic-coglycolic acid) (PLGA) which is densely coated with hydrophilic polymer such as PEG or PLURONIC&#xae; F127, exhibit sustained release of DSP for up to 7 days in vitro. These nanoparticles can be used to prevent corneal graft rejection or corneal neovascularization.

Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization

Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer. In a preferred embodiment the suture materials are made from a poly(hydroxyl acid) such as poly(l-lactic acid) and a polyalkylene oxide such as poly(ethylene glycol) or a polyalkylene oxide block copolymer. The sutures entrap (e.g., encapsulate) one or more therapeutic, prophylactic or diagnostic agents and provide prolonged release over a period of at least a week, preferably a month.

Drug loaded microfiber sutures for ophthalmic application

Growing community of inventors

Baltimore, MD, United States of America

Qingguo Xu